Physician profile
Natalie C Lee
NPI 1447371505
$4,771.24
in general payments reported to CMS, 2019-2025
29 companies · $514 in 2025
The $514 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $292 · 2021: $640 · 2022: $949 · 2023: $993 · 2024: $577 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,510.28 | 2019-2025 | |
| Janssen Biotech, INC. | $631.99 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $589.36 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $499.56 | 2019-2022 | |
| Pfizer INC. | $199.61 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $185.15 | 2020-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $164.63 | 2019-2025 | Rebyota |
| Celgene Corporation | $158.38 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $157.63 | 2019-2024 | |
| Qol Medical, LLC | $119.55 | 2022-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $66.69 | 2021-2023 | |
| Ardelyx, INC. | $37.32 | 2023-2024 | Ibsrela |
| Braintree Laboratories, INC. | $37.19 | 2020-2024 | Sutab |
| Allergan, INC. | $35.25 | 2019-2020 | |
| Daiichi Sankyo INC. | $30.27 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $30.09 | 2023 | Idacio |
| Apollo Endosurgery US INC | $28.26 | 2019 | |
| Merck Sharp & Dohme LLC | $27.81 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $26.37 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $26.05 | 2024 | Resmetirom |
| Shionogi INC | $25.73 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.49 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $25.02 | 2025 | Iqirvo |
| Redhill Biopharma INC. | $24.94 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $24.82 | 2022 | |
| Organon LLC | $22.95 | 2024 | |
| Genzyme Corporation | $21.50 | 2022 | |
| Endo Pharmaceuticals INC. | $21.03 | 2019 | |
| Laborie Medical Technologies Corp. | $18.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.